CJC-1295 and Ipamorelin: why they are paired and how they work
CJC-1295 and Ipamorelin are almost always mentioned together, to the point that some people think they are one substance. In fact they are two different peptides developed by different companies, and it is precisely because their pathways differ that they are often paired. This article explains what each one is, why the logic of pairing them makes sense, and what has been observed in research.
Two doors to the same gland
The release of growth hormone from the pituitary gland is regulated by several signals. The two that matter here are GHRH, a hormone from the hypothalamus that opens the release, and ghrelin, which works through another receptor called GHS-R1a. CJC-1295 is a GHRH analog. Ipamorelin mimics ghrelin. Because the two knock on different doors, the endocrinology literature has long noted that a GHRH signal and a ghrelin pathway signal arriving together produce a larger release than either one alone. That is the theoretical basis for pairing them.
Their position also differs from Tesamorelin, another GHRH analog that has received marketing authorization in some countries. The comparison of Tesamorelin and Ipamorelin is covered separately in this article.
CJC-1295 with DAC and without DAC
The name CJC-1295 is used for two forms that behave very differently, and this often confuses readers.
| With DAC | Without DAC (Mod GRF 1-29) | |
|---|---|---|
| Modification | Given a group that binds blood albumin | Four amino acids replaced for more stability, with no albumin binder |
| Half-life | Around 6 to 8 days in human trials | Much shorter, a matter of minutes |
| Signal pattern | Prolonged stimulation | A brief spike, similar to the natural GHRH pattern |
When CJC-1295 is paired with Ipamorelin on fitness forums, what is meant is often the version without DAC, because its spike is brief like that of Ipamorelin. When reading reviews or product descriptions, check which form is being discussed, because the two behave differently.
What research has observed
For the DAC version of CJC-1295, there are two small studies in healthy adults published in 2005 and 2006. A single injection raised growth hormone levels 2 to 10 times for 6 days or more, and IGF-1 levels 1.5 to 3 times for 9 to 11 days. The second study found that the pulsatile release pattern, like the body's natural pattern, was preserved.
Ipamorelin was first reported in 1998 as a selective growth hormone trigger: the early research observed that it did not also raise ACTH and cortisol the way older compounds of the same kind did. This selectivity is what makes it stand out among growth hormone triggers. In a phase 2 human trial for recovery of bowel function after surgery, Ipamorelin was well tolerated.
A note for athletes
If you take part in official competition that involves doping tests, CJC-1295 and Ipamorelin are on the WADA list, so they are best avoided for as long as you are bound by anti-doping rules.
The wider context of training and recovery is covered in peptides for muscle and the gym, while the checklist for buying peptides online safely helps you read product information before deciding.
Full details on CJC-1295 + Ipamorelin and Ipamorelin are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.
